This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-02. Anything still debated is marked as such rather than presented as settled.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
== History == The first standardized vector, pBR220, was designed in 1977 by researchers in Herbert Boyer's lab. The plasmid contains various restriction enzyme sites and a stable antibiotic-resistance gene free from transposon activities. In 1982, Jeffrey Vieira and Joachim Messing described the development of M13mp7-derived pUC vectors that consist of a multiple cloning site and allow for more efficient sequencing and cloning using a set of universal M13 primers. Three years later, the currently popular pUC19 plasmid was engineered by the same scientists.
The lack of oral activity of DMT is due to rapid metabolism by the enzyme monoamine oxidase A (MAO-A). However, when taken in combination with an irreversible monoamine oxidase inhibitor (MAOI) or a reversible inhibitor of MAO-A (RIMA) such as a harmala alkaloid like harmine or harmaline or a pharmaceutical RIMA like moclobemide, DMT becomes orally active with an extended duration relative to parenteral use of DMT alone. Certain plants like Peganum harmala and the Banisteriopsis caapi used in ayahuasca contain harmala alkaloids which allow DMT to become orally active. When oral DMT is used with an MAOI and the materials are not naturally sourced, the combination is known as pharmahuasca. Changa is a plant-derived form of DMT that is smoked. Smoking and intravenous injection of DMT have extremely intense but very-short-lived effects, whereas intramuscular injection and particularly oral administration with an MAOI have less intense but longer-lasting effects.
==== AICAR transformylase ==== AICAR transformylase requires the coenzyme N10-formyltetrahydrofolate (N10-formyl-THF) as the formyl donor for the formylation of AICAR to FAICAR. However, AICAR transformylase and GAR transformylase do not share a high sequence similarity or structural homology.
{\displaystyle {\begin{aligned}r:\ &\rho \left({\partial _{t}u_{r}}+u_{r}{\partial _{r}u_{r}}+{\frac {u_{\varphi }}{r}}{\partial _{\varphi }u_{r}}+u_{z}{\partial _{z}u_{r}}-{\frac {u_{\varphi }^{2}}{r}}\right)\\&\quad =-{\partial _{r}p}\\&\qquad +\mu \left({\frac {1}{r}}\partial _{r}\left(r{\partial _{r}u_{r}}\right)+{\frac {1}{r^{2}}}{\partial _{\varphi }^{2}u_{r}}+{\partial _{z}^{2}u_{r}}-{\frac {u_{r}}{r^{2}}}-{\frac {2}{r^{2}}}{\partial _{\varphi }u_{\varphi }}\right)\\&\qquad +{\frac {1}{3}}\mu \partial _{r}\left({\frac {1}{r}}{\partial _{r}\left(ru_{r}\right)}+{\frac {1}{r}}{\partial _{\varphi }u_{\varphi }}+{\partial _{z}u_{z}}\right)\\&\qquad +\rho g_{r}\\[8px]\end{aligned}}}
Sources: en.wikipedia.org
=== Associated conditions === Women with PMOS have an increased risk of a range of metabolic, cardiovascular, reproductive and mental health conditions. The likelihood of developing metabolic disorders is about three to seven times higher than in women without PMOS. Insulin resistance is common, even in lean women with PMOS. Overweight or obese women with PMOS are at higher risk of type 2 diabetes than women without PMOS at the same BMI. Lean women with PMOS do not appear to be at higher risk of developing diabetes. Other metabolic and cardiovascular complications commonly associated with PMOS include:
This mating can cause bi-daily surges of prolactin which would normally occur in rodent pregnancy. Prolactin surges initiate the secretion of progesterone which maintains pregnancy and hence can initiate pseudopregnancy. The false maintenance of pregnancy exhibits the outward physical symptoms of pregnancy, in the absence of a foetus. Prolactin receptor activation is essential for normal mammary gland development during puberty in mice. Adult virgin female prolactin receptor knockout mice have much smaller and less developed mammary glands than their wild-type counterparts. Prolactin and prolactin receptor signaling are also essential for maturation of the mammary glands during pregnancy in mice.
A PEGylated lipid is used as an excipient in both the Moderna vaccine and the Pfizer–BioNTech COVID-19 vaccine. Both RNA vaccines consist of Messenger RNA, or mRNA, encased in a bubble of oily molecules called lipids. Proprietary lipid technology is used for each. In both vaccines, the bubbles are coated with a stabilizing molecule of polyethylene glycol. As of December 2020, there is some concern that PEG could trigger an allergic reaction, as appears to have occurred by 19 December, in at least three "Alaska health care worker" people who were administered the Pfizer–BioNTech COVID-19 vaccine. The particular PEGylated molecule in the Moderna vaccine is known as DMG-PEG 2000. Pegvaliase (Biomarin) – PEGylated recombinant phenylalanine ammonia-lyase for the treatment of Phenylketonuria, approved by the FDA for the US in May 2018. Adynovate – PEGylated Antihemophilic Factor VIII for the treatment of patients with hemophilia A. (Baxalta, 2015) Irinotecan liposome (Onivyde) – PEGylated liposomal irinotecan hydrochloride trihydrate for the treatment of metastatic pancreatic cancer in adults proceeding treatment with gemcitabine-based therapy. (Ipsen, 2015) Plegridy – PEGylated Interferon Beta-1a for the treatment of patients with relapsing forms of multiple sclerosis. (Biogen, 2014) Naloxegol (Movantik) – PEGylated naloxol for the treatment of opioid-induced constipation in adults patients with chronic non-cancer pain (un-pegylated methadone can cause adverse gastrointestinal reactions).
Sources: en.wikipedia.org
== Side effects == In a systematic review analyzing data from five cohort studies having 1,085,488 patients, use of gabapentinoids (gabapentin and pregabalin) was associated with an increased risk of thrombotic events (deep venous thrombosis and pulmonary thrombo-embolism) as early as three months of use, and with increased risk of cardiovascular events on prolonged use of more than a year duration. Heart failure was not increased with the use of gabapentinoids.
On June 28, the Senate voted on a procedural motion to begin debate on the bill. Initially, fiscal conservatives Ron Johnson and Rand Paul, along with moderate Thom Tillis, voted against the motion, while fiscal conservatives Rick Scott, Mike Lee, and Cynthia Lummis, as well as moderate Lisa Murkowski, withheld their votes. After hours of negotiations, which resulted in Alaska specific provisions for Murkowski and Republican leadership support for an amendment vote that would result in increased Medicaid cuts targeted at the fiscal conservatives, Johnson, Scott, Lee, Lummis and Murkowski voted for the motion. The passage of the motion to proceed began the "vote-a-rama" process, in which senators can propose an unlimited number of amendments to the bill. Before it could begin, Democrats required the clerks of the Senate to read the entire 940 page bill in order to highlight Medicaid cuts. The vote-a-rama began two days later, on June 30, in the early morning. One of the few successful amendment votes, passing 99–1, removed the proposed AI law moratorium. The vote-a-rama set a record for the most amendment votes in Senate history. After an over 24-hour vote-a-rama, the bill passed the Senate on July 1, 2025, in a mostly party-line 51–50 vote. All Senate Democrats voted against the bill, and Republicans Rand Paul, Thom Tillis, and Susan Collins of Maine broke from their party to vote against the bill as well. Faced with a tie vote, Republican vice president JD Vance cast a tie-breaking vote in favor of the bill.
Numerous social media users, including Americans, expressed their opposition to US foreign policy by sharing the resurfaced copies of the letter and its contents. The Guardian website removed the letter after displaying it for more than 20 years, and TikTok began issuing takedowns of videos featuring the letter. Reporting in The Washington Post suggested that the virality of the letter had been limited prior to media coverage, having never trended on TikTok. Many of the TikTok videos covering the letter were critical of bin Laden, and media coverage had exaggerated its significance while elevating the virality of the letter. In July 2025, TikTok hired Erica Mindel, a former Israel Defense Forces instructor and contractor for the US State Department's Special Envoy to Monitor and Combat Antisemitism, as its Public Policy Manager of Hate Speech. Starting in 2026, TikTok began cracking down on the accounts of Palestinian activists and journalists, including Bisan Owda, who had reported on the human rights abuses taking place in Gaza. Media outlets such as Al Jazeera verified that TikTok's new algorithm hid content depending on the user's region, with the app hiding Palestinian content from users in the Middle East.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.